Health Economics›Non-small cell lung cancer›Advanced or metastatic disease subsequent lines of therapy

Advanced or metastatic disease subsequent lines of therapy

Non-small cell lung cancer · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 8 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	11.6 mo	2	R 573 911 PFS proxy	2
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	13.0 mo	2	R 62 509 PFS proxy	2
Afatinib monotherapy Variant #01	—	R 26 046	28d	—	10.8 mo	2	R 52 091 PFS proxy	1
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	—	16.2 mo	2	R 32 087 PFS proxy	1
Erlotinib monotherapy Variant #01	—	R 13 907	28d	1.8 mo	7.3 mo	2	R 27 814 PFS proxy	8
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	2.9 mo	8.3 mo	6	R 79 350 PFS proxy	9
Docetaxel and Nintedanib Variant #01	—	R 9 577	21d	3.4 mo	10.1 mo	2	R 19 155 PFS proxy	2
Afatinib and Paclitaxel Variant #01	—	R 9 294	7d	5.6 mo	—	2	R 18 588 PFS proxy	1
Gefitinib monotherapy Variant #01	—	R 4 278	28d	3.4 mo	7.6 mo	2	R 8 556 PFS proxy	6
Docetaxel monotherapy Variant #02	—	R 2 921	28d	3.2 mo	9.8 mo	2	R 5 843 PFS proxy	39
Docetaxel monotherapy Variant #02	KRAS	R 2 921	28d	3.2 mo	9.8 mo	2	R 5 843 PFS proxy	39
Docetaxel monotherapy Variant #02	MET	R 2 921	28d	3.2 mo	9.8 mo	2	R 5 843 PFS proxy	39
Docetaxel and Nivolumab Variant #01 Partial	—	R 1 948	28d	—	23.1 mo	2	R 3 895 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	9.5 mo	7	R 11 705 PFS proxy	1
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	9.5 mo	12	R 5 490 PFS proxy	1
Icotinib monotherapy Variant #01 Partial	—	—	28d	4.6 mo	—	26	—	1
Placebo Partial	—	—	—	—	6.3 mo	—	—	5
Amrubicin monotherapy Variant #01 Partial	—	—	21d	3.6 mo	—	2	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	13.3 mo	2	—	2
Adagrasib monotherapy Variant #01 Partial	KRAS	—	28d	5.5 mo	—	2	—	1
Sotorasib monotherapy Variant #01 Partial	KRAS	—	28d	5.6 mo	—	2	—	1
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	17.2 mo	2	—	1
S-1 monotherapy Variant #01 Partial	—	—	21d	—	12.8 mo	2	—	1
Best supportive care Partial	—	—	—	—	4.6 mo	—	—	1

24 of 24 regimens shown